Aarti Drugs has reported results for fourth quarter and year ended March 31, 2021.
The company has reported 11.17% fall in its net profit at Rs 50.24 crore for the quarter under review as compared to Rs 56.56 crore for the same quarter in the previous year. However, total income of the company increased by 11.23% at Rs 452.93 crore for Q4FY21 as compared Rs 407.19 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported 12.25% fall net profit attributable to owners at Rs 51.65 crore for the quarter under review as compared to Rs 58.86 crore for the same quarter in the previous year. However, total income of the company increased by 11.56% at Rs 502.72 crore for Q4FY21 as compared Rs 450.63 crore for the corresponding quarter previous year.
For the year ended March 31, 2021, the company has reported a rise of 89.95% in its net profit at Rs 257.71 crore as compared to Rs 135.67 crore for the previous year. Total income of the company increased by 17.44% at Rs 1921.31 crore for year under review as compared to Rs 1635.98 crore for year ended March 31, 2020.
For the year ended March 31, 2021, on the consolidated basis, the company has reported a rise of 98.31% in its net profit attributable to owners at Rs 280.41 crore as compared to Rs 141.40 crore for the previous year. Total income of the company increased by 19.46% at Rs 2159.30 crore for year under review as compared to Rs 1807.57 crore for year ended March 31, 2020.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1935.25 |
| Dr. Reddys Labs. | 1245.50 |
| Cipla | 1438.75 |
| Zydus Lifesciences | 1150.50 |
| Lupin | 2496.05 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: